Genetic Polymorphisms of Serine Hydroxylmethyl Transferase 1 (SHMT1) in Patients With Parkinson's Disease

Assiut University1 site in 1 country80 target enrollmentJanuary 31, 2021

ConditionsStudy the Role of SHMT1 Polymorphism in Parkinson Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Study the Role of SHMT1 Polymorphism in Parkinson Disease
Sponsor: Assiut University
Enrollment: 80
Locations: 1
Primary Endpoint: polymorphism of SHMT1gene
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Parkinson Disease (PD) is the most common movement disorder and represents the second most common degenerative disease of the central nervous system . SHMT has been shown to be associated with various diseases.

Detailed Description

This case -control observational prospective study will conducted on 40 patients with PD.

Registry

clinicaltrials.gov

Start Date

January 31, 2021

End Date

January 2022

Last Updated

4 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Assiut University

Responsible Party

Principal Investigator

Effat AETony, MD

professor of internal medicine

Assiut University

Eligibility Criteria

Inclusion Criteria

•Patients age ≥ 50 years.
•Patients with PD diagnosed according to the United Kingdom Parkinson's Disease Society Brain Bank (UK PDS Brain Bank diagnostic criteria)

Exclusion Criteria

•Patients with parkinsonian plus syndrome
•Patients with secondary parkinsonism
•Patients with other chronic comorbidities (renal, hepatic, and endocrinal disturbances and chronic chest disease.)
•Past and /or present history of epilepsy.
•Patients with disturbed conscious level.